Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ENTB shareholders may like to review this communication from Sept19/17 especially considering that ENTB/ZANDER will be the first beneficiary of the progress outlined. GLTA.
Regen BioPharma Issues End of Fiscal Year Shareholder Letter
PR Newswire PR NewswireSeptember 19, 2017
SAN DIEGO, September 19, 2017 /PRNewswire/ --
Regen BioPharma Inc. (RGBP) and (RGBPP) President Dr. Harry Lander issued the following fiscal year end shareholder letter:
As the end of Regen's fiscal year 2017 approaches on September 30th, I would like to summarize our progress during the past twelve months and look to the future.
The Marketplace:
Our decision to focus on small molecules to activate and inhibit our primary target of interest, NR2F6, seems prescient. The M&A market indicates that the autoimmunity and immuno-oncology fields are even hotter at the end of the year than they were at the beginning. Although there have been many transactions over the past twelve months, two very recent deals further support this assertion: the $2.3 billion acquisition of IFM Therapeutics, Inc. by Bristol Myers Squibb (which I commented on previously (http://www.prnewswire.com/news-releases/regen-biopharma-inc-addresses-potential-impact-of-recent-bristol-myers-squibb-23-billion-acquisition-of-ifm-therapeutics-639392183.html), and the $11.9 billion acquisition of Kite Pharmaceuticals by Gilead (http://www.gilead.com/news/press-releases/2017/8/gilead-sciences-to-acquire-kite-pharma-for-119-billion).
A Look Back at our Success:
The scientific program focusing on identifying and optimizing small molecule compounds that activate or inhibit NR2F6 and directly inhibit or activate the immune system, respectively, is proceeding well. To our great excitement, we believe we are only three or four months away from having an optimized activator in hand, which we can then test in several animal models of autoimmunity. Similarly, we also expect to have an optimized inhibitor a few months afterward (in calendar Q1 of 2018), which we can then test it in several animal models of cancer.
Plans for the Immediate Future:
We continue to have discussions with multiple big pharma companies. To create the most value for our shareholders, we have elected to continue to develop the NR2F6 program in-house prior to entering into any potential partnerships. The more mature the products, the greater their valuation in the marketplace.
We are now in the process of identifying the major indications on which we will focus our efficacy studies. Obviously, the market size of an indication is important, but equally or even more important is the likelihood of success. Therefore, although we already have a preferred list of indications, we will test these compounds for efficacy in many models of autoimmunity and cancer. Our goal in 2018 is to develop both an activator and inhibitor of NR2F6 that is effective and not toxic in animal models. At that point, we will begin experiments and process manufacturing, which will enable us to apply for testing these compounds in humans.
The drug development process is slow and steady. However, we have had no scientific setbacks, and the small molecule drugs that we are developing are performing exactly as we had hoped they would. This is not usually the case in science and we remain laser-focused on achieving the scientific goals we have set out to achieve. Thus far, we have met each and every scientific target, and we believe that our planned scientific efforts in 2018 will greatly increase the likelihood of striking strategic partnerships with one or more large pharmaceutical companies in the near future.
With warm regards,
Harry Lander
President and Chief Scientific Officer
Take a look $ENTB huge company dd profile http://www.frontpagestocks.com/entest-biomedical-inc-entb/
$ENTB up 26% on ALERT as the company is "Progressing to Treat/Stop Cancer-Auto Immune Diseases-New Drugs in Pipeline" http://www.zandertherapeutics.com http://fb.me/1gejtml4c
Ok , thank you for clarification , Ron
We get shares in ZANDER based on our holding of ENTB.
So are we getting shares in ENTB/ Zander , cash or what? I don't quite understand
Still money in the bank.Divy shares should list for at least $1.00 based on recent sale of 900,000 shares.Divy should work out to 5.887% of all outstanding entb shares.
Kind of strange , no communication on it anymore. Expected some word by now
Good point.Waiting for EFFECT filing re the S1 from SEC.Anyone know what the maximum time frame is.Perhaps 3 months-would be beginning of January then.
There have and are always bids.perhaps on Canadian brokerages the bids do not show.gltu
How can ENTB keep trading on offer at .035 and higher and there are never any bids?
something ain't right
$ENTB ENTEST BIOMEDICAL, INC. FORM 10-K (Annual Report)
Filed 11/30/17 for the Period Ending 08/31/17
https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12407222
$ENTB Subsidiary Zander Therapeutics Has 4 Veterinary Products In The Pipeline For Dogs, Cats & Horses https://seekingalpha.com/instablog/32618395-small-cap-solutions-llc/5032385-entb-subsidiary-zander-therapeutics-4-veterinary-products-pipeline-dogs-cats-and-horses
Entest Biomedical In (ENTB) 0.0328 +0.0028 (9.33%)
Volume: 73,238
$ENTB up 9.33% on Good volume! Zander Therapeutics-Creating 4 New Cutting Edge Veterinary Drugs/Treatments Cancer-Auto Immune Diseases Ticked Up & Closed Up Wed Good News should continue Uptrend. Former PETCO CEO Joins Team. https://seekingalpha.com/p/30hdp
Zander will reap this great progress.Regen BioPharma, Inc. Begins In Vivo Assessment of Small Molecule Agonists to NR2F6 Nuclear Receptor
Early data suggest molecules are stable and may be delivered orally
NEWS PROVIDED BY
Regen BioPharma, Inc.
18:26 ET
SHARE THIS ARTICLE
SAN DIEGO, California, November 27, 2017 /PRNewswire/ --
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has initiated in vivo and ex vivo assessments to determine the effects of some of the Company's NR2F6 small molecule agonists in live rats and in tissues derived from humans and rats. Key attributes that are being measured include pH, plasma and liver microsomal stability, along with pharmacokinetics.
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity. The program also aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system..
"Initial studies are quite positive. Our compounds are stable at pH 2 and 7, stable in rat and human plasma, additionally one of our compounds shows very nice pharmacokinetics with an oral or intravenous half-life of about 2.5 hrs," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. "Getting this data early in the process informs us of any liabilities the compounds may have which we would need to address via medicinal chemistry. So far, these molecules look like they will be orally deliverable and will not require too much more tweaking before we can start testing them for efficacy."
"I am very pleased that we have entered the phase of development where we are now testing these drugs in vivo and ex vivo," says David Koos, Ph.D., Chairman & CEO Regen BioPharma Inc. "These experiments we are currently involved with now will determine the path we proceed with going forward."
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Silly to sell when waxing for effective date to get free shares.
Not the first time I’ve seen people shoot selves in foot
Patience is definitely a virtue with this stock.convinced that it will pay off.
I did buy twice at the ask but a few months ago when it kept dropping into mid teens I left a bid up for a couple weeks at bid and the bid even dropped below that and never got filled.
I also had a couple at ask this year that didn't get filled but had it at AON
Just looked been here since '13 myself
I have held for almost 4 years.the ZANDER dividend shares should more than recoup my investment.did u mean buy at the ask?gltu.
I tried buying a couple months ago at the bid and was never successful , I don't think there are many shares to be had. Wish I had more , have been sitting here for 3 years or so and am still willing to wait.
Wish i had some extra money to add but can't right now.
Share split awhile back hurt me but have been able to get back to a reasonable PPS. Just waiting for the reward IMO
Go ENTB and Zander.
Probably the same dumbass that wants to buy more at .0151 imo I do not think that they will be successful.
Who is the dumbass that just did a market sell for 25k
EXCELLENT. once investors connect ZANDER/ENTB to the REGEN progress, demand for the soon new ZANDER shares will be astronomical imo.
NEWS...Regen BioPharma Inc. Chairman Discusses the Rationale for Pursuing Autoimmune Indications by Activating the Nuclear Receptor NR2F6Font 11/16/17 | PR Newswire
SAN DIEGO, November 16, 2017 /PRNewswire/ --
18 months ago, Regen BioPharma Inc. (OTCQB: RGBP)(OTCQB: RGBPP) commenced a program to identify small molecules that inhibit the NR2F6 nuclear receptor. The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. Regen BioPharma believes that by inhibiting the NR2F6 nuclear receptor, one can unleash the cancer-killing potential of a patient's own immune system. Regen is also engaged in the identification of small molecules which activate the NR2F6 nuclear receptor that can be utilized to develop small molecule therapies for autoimmune disorders
"The rationale for activating the NR2F6 nuclear receptor (also known as a checkpoint) is straightforward - if inhibiting the checkpoint activates the immune system and thus helps kill cancer cells, then conversely, activating the checkpoint should suppress the immune system and thus be useful in diseases where the immune system is over-activated, such as rheumatoid arthritis, lupus, colitis and many other autoimmune diseases," says David Koos, Ph.D., Chairman and CEO of Regen. "Our program stands out because we are working with small molecules delivered in pill form. Other biotechnology companies are focused on antibodies that have much more cumbersome delivery methods (hospital stays with IV injections, etc.). The benefits of small molecules are many, including cost of manufacturing, flexibility in dosing and routes of administration, potential control of toxicity and intellectual property protection."
There are currently about 9 companies working on activating immune checkpoints, but Regen appears to be the sole company known to be working on utilizing small molecules to activate immune checkpoints (https://www.biocentury.com/bc-innovations/strategy/2017-08-10/how-immuno-oncology-targets-are-spawning-new-therapies-
Waiting for EFFECT notice from SEC. Usually 6 weeks after S1 filing.Next week maybe.
Whatever happened to this dividend to stockholders ? Did I miss something ?
$ENTB Entest BioMedical Inc. is the parent company of Zander Therapeutics Inc Zander is looking to increase the quality of life in animals through therapies involving small molecules, stem cell treatments and the body’s own immune system.
http://www.frontpagestocks.com/entest-biomedical-inc-entb/ … @frontpagestocks
I don't know what stock you are referring to. The last financial report for ENTB was June 22.
Correct, this is an annual report from 8/31 year end...certainly you can not be serious
All this NR2F6 focus will definitely benefit ENTB/ZANDER success. Regen BioPharma's Chief Scientific Officer Explains the Link Between its NR2F6 Medicinal Chemistry and Three-Dimensional X-Ray Structure Programs
SAN DIEGO, November 8, 2017 /PRNewswire/ --
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) recently began a program to determine the three-dimensional structure of the NR2F6 nuclear receptor. In addition, the Company recently reported that its NR2F6 medicinal chemistry program identified key structural elements in small molecules that make them active and specific towards the NR2F6 target.
These two programs are integrally linked. Success in determining the structure of NR2F6 will inform future work on medicinal chemistry, as well as confirm the exact nature of the interaction between Regen's small molecules and NR2F6.
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity and Lupus.
"The object of the three-dimensional x-ray structure program is to shed light on exactly how our small molecules bind to and modulate NR2F6 activity. Imagine the NR2F6 nuclear receptor (protein) has a specific pocket where activators bind. We don't know the shape of that pocket, although we are beginning to infer it from the key structural elements of our small molecules that bind and activate it. With the actual structural data in hand from the three-dimensional x-ray structure, we will be able to see nuances that will both explain our success so far and will guide us as we make more small molecules. This will also help us improve on the small molecules we have made so far," said Harry Lander, President and Chief Scientific Officer of Regen BioPharma Inc.
"The three-dimensional x-ray structure program, coupled with our medicinal chemistry program will enhance Regen's drug development process. These two programs linked together will give us a much clearer picture of what is actually happening at the molecular level," said David Koos, Ph.D., Chairman and CEO of Regen BioPharma Inc. "That, in turn, will help any of our potential co-development partners feel more comfortable with our mechanism of action."
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is targeting the immunotherapy space, seeking to rapidly advance small molecule immunological therapies to treat cancer and autoimmunity through pre-clinical and Phase I/ II clinical trials. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com
Why can't it just be timely like most other legitimate companies? OTC rules state that quarterly reports get 45 days. Annual reports get 90 days.
Nice try...year-end is 8/31 they have 90 days which puts them at the end of November.
Quarterly report is 45 days late. Is ENTB going dark like BMSN did?
$ENTB is specifically focused on animal therapies that address unmet medical needs. Strong bullish mover. http://www.frontpagestocks.com/entest-biomedical-inc-entb/
Regen BioPharma, Inc. Announces Former Eli Lilly Executive and Current CVS Board Member will Lead Newly Formed Business Advisory Board (BAB)
PR Newswire PR NewswireOctober 30, 2017
CVS Health, Inc. Director Jean-Pierre Millon will serve as Chairman of the BAB, Roger Formisano and Robert Hopkins to serve as BAB board members for Regen BioPharma Inc.
SAN DIEGO, October 30, 2017 /PRNewswire/ --
Regen BioPharma, Inc. (RGBP) and (RGBPP) announced that former Eli Lilly executive Jean-Pierre Millon will serve as chairman of its newly formed business advisory board (BAB). The Company also announced that two esteemed life science and healthcare executives have agreed to serve as members of the BAB. The advisory board will assist Regen's management team in evaluating partnership and licensing opportunities related to the company's intellectual property including its NR2F6 program.
"We are pleased to have such a highly accomplished and respected group of individuals join our advisory board," said Todd Caven, CFO at Regen BioPharma. "Their collective insight and expertise will be extremely helpful to the executive team as we evaluate various opportunities with respect to our intellectual property portfolio in 2018 and beyond."
The initial members of the board are as follows:
Jean-Pierre Millon (Chairman) is a director at CVS Health, Inc. [NYSE:CVS]. His board position evolved after a CVS merger with Caremark in April 2007 and Caremark's purchase of AdvancePCS, a pharmacy benefit management company, in 2004. Before his post with Caremark, Mr. Millon was named to the board of AdvancePCS in 2000 upon the merger of Advance Paradigm and PCS Health Systems. He was president and chief executive officer of PCS from 1996 to 2000. Prior to joining PCS, Mr. Millon was an executive with Eli Lilly and Company. His career with Lilly and its subsidiaries spanned two decades and was highlighted by leadership positions in the United States and executive posts in Asia, Europe and the Caribbean Basin. A native of Paris, Mr. Millon is fluent in French, English, German and Spanish.
Roger Formisano, PhD (board member) is Vice-President for Leadership and Strategic Development at UW Health in Madison, Wisconsin, where he designed, developed and delivered a Physician Leadership Development Program, grooming mid-career physicians for leadership roles in the $3.5 billion UW Health organization. He is a recognized thought leader on strategy, entrepreneurship and organizational effectiveness and has distinguished himself as a professor, an author, and a senior executive. He has served as a professor of entrepreneurship and business at UW-Madison School of Business, ISTCE-INDEG in Lisbon, Portugal and HEC Paris.
Robert Hopkins (board member) spent his career in hospital systems management, including C-level positions in marketing, operations, physician practice management, business development and as a chief executive. He earned his B.A. in Journalism and MBA from the Smeal College of Business at Pennsylvania State University. Additionally, he completed the Graduate Certificate Program in Medical Ethics at Albany Medical College. He retired in 2015 and is a private investor, including investment in Regen BioPharma.
"The marketplace for small molecule drug platforms in the immune oncology and autoimmunity sectors of pharmacology continues to attract great interest from pharmaceutical firms throughout the world," said David Koos, Chairman and CEO of Regen. "Within the small molecule universe, Regen possesses an extremely unique position as it pertains to NR2F6. We look forward with great anticipation to the insight that we will receive from our advisory board as to the optimal strategies to expand our NR2F6 program and increase shareholder value."
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (RGBP) and (RGBPP). The Company is targeting the immunotherapy space, seeking to rapidly advance small molecule immunological therapies to treat cancer and autoimmunity through pre-clinical and Phase I/ II clinical trials. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
$ENTB LINK on Article @seekingalpha.com Raises $900,000 May Be Used For Subsidiary - Zander - Development Of New Drugs &Treatments For Veterinary
https://seekingalpha.com/instablog/32618395-small-cap-solutions-llc/5061373-entb-subsidiary-zander-therapeutics-raises-900000-awaiting-clearance-sminus-1-filing
Thank you very much for the detailed response. Didn't know we are still dealing with FDA approval here. Hopefully it's an easier and faster process than FDA approval for human drugs.
$ENTB Subsidiary Zander Therapeutics Raises $900,000 While Awaiting Clearance Of Their S-1 Filing/Registration
https://seekingalpha.com/instablog/32618395-small-cap-solutions-llc/5061373-entb-subsidiary-zander-therapeutics-raises-900000-awaiting-clearance-sminus-1-filing
Partial answer for you.GLTU.The Company estimates that it will require $1,500,000 to complete medicinal chemistry studies with regards to the Company’s products in development. Medicinal chemistry is the process by which trained chemists modify a starting compound (called a parent compound) in an effort to optimize its characteristics such as binding affinity and toxicity profile. The Company estimates that it will require an additional require an additional $1,500,000 to complete pre-clinical studies with regards to the Company’s products in development. Pre-clinical studies refer to detailed cellular and animal studies that measure the toxic effects of the drug, how long it stays in the blood stream, efficacy, where it goes in the body and the best way to formulate and deliver the drug. The Company estimates that it will require a further additional $2,000,000 to complete studies required in order that Investigational New Animal Drug (INAD) Applications may be submitted to the United States Food and Drug Administration (FDA) with regards to the Company’s products in development. INAD-enabling studies include using the drug in its final commercial manufactured form in the target animals of interest to show efficacy in the field and to look for toxicity.
The fact that Zander was able to sell 900K shares at $1.00 each is intriguing as it is a vast change from the .01-.05 sales of shares for money going on at Regen.
I do not know anything about Veterinary issues. Can someone with knowledge post whether or not veterinary medicines are regulated, by whom and if so, how long to bring a treatment to approval?
Or, let's say, Zander discovers a cell treatment for arthritis in dogs, can they immediately sell it or does it have to be reviewed and get approval first from some entity?
Thanks
for those who have been around for a while. do you remember when inventor1 invested $400K in RGBP shares for $1 a piece a few years ago? Look how much he has lost since that investment
Followers
|
376
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
38376
|
Created
|
08/14/09
|
Type
|
Free
|
Moderators |
Regen BioPharma Issues End of Fiscal Year Shareholder Letter
PR Newswire PR NewswireSeptember 19, 2017
SAN DIEGO, September 19, 2017 /PRNewswire/ --
Regen BioPharma Inc. (RGBP) and (RGBPP) President Dr. Harry Lander issued the following fiscal year end shareholder letter:
As the end of Regen's fiscal year 2017 approaches on September 30th, I would like to summarize our progress during the past twelve months and look to the future.
The Marketplace:
Our decision to focus on small molecules to activate and inhibit our primary target of interest, NR2F6, seems prescient. The M&A market indicates that the autoimmunity and immuno-oncology fields are even hotter at the end of the year than they were at the beginning. Although there have been many transactions over the past twelve months, two very recent deals further support this assertion: the $2.3 billion acquisition of IFM Therapeutics, Inc. by Bristol Myers Squibb (which I commented on previously (http://www.prnewswire.com/news-releases/regen-biopharma-inc-addresses-potential-impact-of-recent-bristol-myers-squibb-23-billion-acquisition-of-ifm-therapeutics-639392183.html), and the $11.9 billion acquisition of Kite Pharmaceuticals by Gilead (http://www.gilead.com/news/press-releases/2017/8/gilead-sciences-to-acquire-kite-pharma-for-119-billion).
A Look Back at our Success:
The scientific program focusing on identifying and optimizing small molecule compounds that activate or inhibit NR2F6 and directly inhibit or activate the immune system, respectively, is proceeding well. To our great excitement, we believe we are only three or four months away from having an optimized activator in hand, which we can then test in several animal models of autoimmunity. Similarly, we also expect to have an optimized inhibitor a few months afterward (in calendar Q1 of 2018), which we can then test it in several animal models of cancer.
Plans for the Immediate Future:
We continue to have discussions with multiple big pharma companies. To create the most value for our shareholders, we have elected to continue to develop the NR2F6 program in-house prior to entering into any potential partnerships. The more mature the products, the greater their valuation in the marketplace.
We are now in the process of identifying the major indications on which we will focus our efficacy studies. Obviously, the market size of an indication is important, but equally or even more important is the likelihood of success. Therefore, although we already have a preferred list of indications, we will test these compounds for efficacy in many models of autoimmunity and cancer. Our goal in 2018 is to develop both an activator and inhibitor of NR2F6 that is effective and not toxic in animal models. At that point, we will begin experiments and process manufacturing, which will enable us to apply for testing these compounds in humans.
The drug development process is slow and steady. However, we have had no scientific setbacks, and the small molecule drugs that we are developing are performing exactly as we had hoped they would. This is not usually the case in science and we remain laser-focused on achieving the scientific goals we have set out to achieve. Thus far, we have met each and every scientific target, and we believe that our planned scientific efforts in 2018 will greatly increase the likelihood of striking strategic partnerships with one or more large pharmaceutical companies in the near future.
With warm regards,
Harry Lander
President and Chief Scientific Officer
http://www.barchart.com/headlines/story/8402740/entest-biomedical-inc-in-discussions-to-acquire-nanotechnology-delivery-system-for-cancer-therapy
| Brian Devine, Chairman Business Advisory Board Brian is the former Chairman, CEO, and President of PETCO, where he oversaw the company’s expansion from $80 million to approximately $5 billion in sales. He became Chairman Emeritus at Petco Holdings, Inc. in 2016. Prior to that, he held leadership roles at Toys R Us, including Senior Vice President, Director of Stores for the U.S and Canada. Brian served as a Director at National Retail Federation Inc., Retail Industry Leaders Association, Students in Free Enterprise, Georgetown University Board of Regents, Georgetown University College Board of Advisors, San Diego International Sports Council, and the San Diego Padres. He also served as Director, Chairman of Real Estate Committee, Member of Executive Committee and Member of Nominating Committee at Wild Oats Market prior to it being sold to Whole Foods. He currently is on the Board of Directors of the Ron Fowler School of Business at San Diego State University, the San Diego Sports Alliance, the San Diego Hall of Champions, and on private company boards. |
http://www.zandertherapeutics.com
?Zander Therapeutics is a biotechnology company focused on veterinary therapies that enlist the animals’ own immune system. Zander’s main areas of interest include: autoimmune disorders such as arthritis, immunotherapies for cancer treatment in canines and bone marrow suppression therapy for animals treated with chemotherapy and radiation therapy. ? | |
??Learn more about bone marrow and aplastic anemia therapy as well as small molecule targeting cancer stem cell genes.
Address: Zander Therapeutics, Inc. 4700 Spring Street, Suite 304 La Mesa, CA 91942 U.S.A. ?venturebridge@gmail.com Telephone: (619) 702-1404 Fax: (619) 330-2328 |
| David R. Koos, PhD, DBA Chairman and Chief Executive Officer David Koos is the Founder, Chairman & CEO of Entest BioMedical Inc. Dr. Koos has over 32 years of investment banking and venture capital experience with a primary focus on fully reporting medical and biotechnology ventures. He holds a Ph.D. degree in Sociology and a Doctor of Business Administration in Finance. Additionally, he has authored or co-authored several peer reviewed journal articles primarily on biotechnology related subjects. |
| ?Harry Lander, PhD, MBA President and Chief Scientific Officer Harry Lander has over 20 years of professional scientific, business and financial management experience related to biomedical research. He has a deep knowledge of operations and research administration. Dr. Lander has a team-oriented management style founded on outstanding communication and interpersonal skills. Highly effective at strategic planning, problem solving and operational excellence. Dr. Lander has extensive relationships with large and small biotechnology / pharmacology companies and entities that Regen BioPharma expects to leverage for company growth. Formerly he has served as Research Chief / Administration for Sidra Medical and Research Center (Doha, Qatar), Assistant Provost for Weill Cornell Medical College (Cornell University), along with serving as Assistant Dean for Research Administration at Weill Cornell Medical College (Cornell University). |
| ?Todd S. Caven Chief Financial Officer Todd S. Caven is an accomplished executive with 30 years of experience in corporate finance, taxation, mergers & acquisitions, corporate valuations and financing activities for various types of transactions. In March of 2009, Mr. Caven co-founded Saguaro Capital Partners, an Arizona based firm that raises growth capital for medical device, pharmacology and technology based companies throughout the western United States. In 2003, Mr. Caven founded Rock Ridge Enterprises, a Minnesota-based boutique Private Equity firm that focuses on the acquisition of manufacturing, distribution, construction and business services firms in the upper Midwest. Prior to founding Rock Ridge Enterprises, he served as the CFO of Atterro Human Capital Group (formerly Pro Staff), a $500 million privately held firm in the Staffing and Recruiting industry. Prior to Atterro, Todd held senior-level finance and marketing positions at Nordic Track and the Carlson Companies, both in Minneapolis, Minnesota. He started his career in corporate finance at Amoco Corporation in Chicago, Illinois (now British Petroleum). Todd earned a Bachelors degree in Accounting from the Tippie College of Business at the University of Iowa, and he received an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University. |
| Thomas Donnelly, DVM Senior Veterinary Advisor ? Tom is a board-certified specialist in the field of laboratory animal medicine. He is also Adjunct Associate Professor at Tufts University Cummings School of Veterinary Medicine and Professor (teaching & research) at Ecole Nationale Veterinaire d’Alfort. He provides regulatory guidance, research advice, medical attention and welfare supervision to researchers using animals in scientific investigation and testing. Tom is a board-certified specialist in the field of exotic mammals, and sees primary care and referred patients. His work links the understanding of animal diseases and their complexities with the development of novel therapies for humans and animals. |
| Linda L. Black, DVM, PhD Senior Veterinary Advisor Linda is a leading researcher, published author and currently COO and Vice President of Clinical Science for Medicus Biosciences, a biotech company focused on drug delivery for ophthalmology, advanced wound healing, osteoarthritis, and regenerative medicine applications for pets and people. She has extensive experience in veterinary stem cell research and commercialization. She holds a PhD in Molecular and Cell Biology from The Wistar Institute at University of Pennsylvania School of Medicine, a DVM from University of Wisconsin School of Veterinary Medicine and attended undergraduate training at the University of California at Davis. She completed her post doctoral fellowship at GlaxoSmithKline. |
| ?Thomas Ichim, PhD Senior Research Consultant Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. He spent over seven years as President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with the FDA. Subsequent to the acquisition of Medistem by Intrexon, in a deal worth $26 million, Dr. Ichim was brought on to the parent company in its cell engineering unit as Vice President of Cellular Therapy. |
| ?Debbie Dorsee Director of Business Development The Dorsee Company, founded by Debbie Dorsee, is a leader in public relations for businesses and individuals. With an integrated focus on community relations, marketing, fundraising/capital raising, and business development, The Dorsee Company offers a unique promotional approach that opens doors, forges partnerships, and drives results. ? Debbie Dorsee, a San Diego native, founded The Dorsee Company in 2003. Drawing from her life’s fabric of political campaigns, social events and promotional fundraising, she uses her behind-the-scenes knowledge and community contacts to promote public awareness and drive business results. Debbie was the recipient of the San Diego North Chamber of Commerce’s Volunteer of the Year honor and was named one of San Diego Metropolitan Magazine’s Metro Movers to Watch |
Jonathan Baell, PhD
Scientific Advisory Board
Dr. Baell is a professor or Medicinal Chemist at Monash University (Australia) whose research is focused on the discovery of new medicines for treating diseases with an unmet medical need. A proven record of undertaking original research with a total of 120 publications and patents. He is published in top-ranked journals in the field (e.g. 12 in Journal of Medicinal Chemistry, Nature Chemical Biology,Nature). He has 40 granted patents listed in www.lens.org.
He has won a national award for my discovery of a new class of potential multiple sclerosis therapeutics. Additionally he has achieved successful outcomes in a diverse array of drug discovery arenas, from rational design of peptidomimetics to heterocyclic drug discovery.
For the period 2012-16, Dr. Baell is Chief InvestIgator on competitive grants that currently are totalling $4.73M. In addition, he has been awarded a prestigious NHMRC Senior Research Fellowship for the period 2012-2016. In 2011 and elected as the Australian representative to the Board of Directors for the Inaugural International Chemical Biology Society and appointed Chair of Membership.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |